Abstract:fi2AR is an important drug target protein involving many diseases. Biased drugs induce specific signaling and provide additional clinical utility to optimize fi2AR-based therapies. However, the biased signaling mechanism has not been elucidated. Motivated by the issue, we chose four agonists with divergent bias (balanced agonist, G-protein-biased agonist, and fi-arrestin-biased agonists) and utilized Gaussian accelerated molecular dynamics simulation coupled with a dynamic network to probe the molecular mechanisms of distinct biased activation induced by the structural differences between the four agonists. Our simulations reveal that the G-protein-biased agonist induces an open conformation with the outward shifts of TM6 and TM7 for the intracellular domain, which will be beneficial to couple G protein. In contrast, the fi- arrestin-biased agonists regulate an occluded conformation with a slightly outward movement of TM6 and an inward shift of TM7, which should favor fi-arrestin signaling. The balanced agonist does not induce an observable outward shift for TM6 but, along with a slight tilt for TM7, leads to an inactive-like conformation. In addition, our results reveal the first time that ICL3 presents specific conformations with different agonists. The G-protein-biased agonist drives ICL3 to open so that the G protein-binding pocket can be available, while the fi-arrestin-biased agonists induce ICL3 to form a closed conformation with a stable local a-helix. MM/PBSA analysis further reveals that the hydroxyl groups in the resorcinol of the G-protein-biased agonist form strong interactions with Y5.38 and S5.42, thus preventing tilting of the TM5 extracellular end. The catechol of the balanced agonist and the fi-arrestin-biased ones induces the rearrangement of two hydrophobic residues F6.52 and W6.48. However, different from the balanced agonist, the ethyl substituent of fi-arrestin-biased agonists forms additional hydrophobic interactions with W6.48 and F6.51 after the rearrangement, which should contribute to the fi-arrestin bias. The shortest pathway analysis further reveals that the three residues Y7.43, N7.45, and N7.49 are crucial for allosterically regulating G-protein-biased signaling, while the two residues W6.48 and F6.44 make an important contribution to regulate fi-arrestin-biased signaling. For the balanced agonist NE, the allosteric regulation pathway simultaneously involves the residue associated with G-protein-biased signaling like S5.46 and the residues related to fi-arrestin-biased signaling like W6.48 and F6.44, thus producing unbiased signaling. The observations could advance our understanding of the biased activation mechanism on class A GPCRs and provide a useful guideline for the design of biased drugs.

Biased signaling due to oligomerization of the G protein-coupled platelet-activating factor receptor

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor

Biased Activation Mechanism Induced by GPCR Heterodimerization: Observations from Μor/δor Dimers

Inverse Regulation of C-C Chemokine Receptor 3 Oligomerization by Downstream Proteins Indicates Biased Signal Transduction Pathways.

Membrane-Mediated Oligomerization of G Protein Coupled Receptors and Its Implications for GPCR Function

Stabilised D R G-protein coupled receptor oligomers identify multi-state β-arrestin complexes

Structural basis for signal recognition and transduction by platelet-activating-factor receptor

Structural Basis of Orientated Asymmetry in a Mglu Heterodimer

Understanding The Regulation Mechanisms Of Paf Receptor By Agonists And Antagonists: Molecular Modeling And Molecular Dynamics Simulation Studies

GPCR Structure and Function Relationship: Identification of a Biased Apelin Receptor Mutant.

Structure and dynamics determine G protein coupling specificity at a class A GPCR

Molecular Mechanisms of Diverse Activation Stimulated by Different Biased Agonists for the 2-Adrenergic Receptor

[Research Progress in Signal Bias of G Protein-Coupled Receptor and Its Mechanism].

Rearrangement of the Transmembrane Domain Interfaces Associated with the Activation of a GPCR Hetero-Oligomer.

Mechanisms of signalling and biased agonism in G protein-coupled receptors

Single-molecule Imaging Reveals Dimerization/oligomerization of CXCR4 on Plasma Membrane Closely Related to Its Function

Multiple Ligand-Specific Conformations of the Β2-Adrenergic Receptor

Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling

Anionic phospholipids control mechanisms of GPCR-G protein recognition

LIPIDS MODULATE THE DYNAMICS OF GPCR:β-ARRESTIN INTERACTION